Recommended High-Yield ETF: Schwab U.S. Dividend Equity ETF
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Source: Fool
- Income and Growth Balance: The Schwab U.S. Dividend Equity ETF boasts a dividend yield of 3.25% and has risen 19% year-to-date in 2026, delivering slightly lower growth than the S&P 500 while providing nearly three times the dividend income, indicating a strong balance between income and growth.
- Expense Ratio Advantage: With an expense ratio of just 0.06%, investors pay only $6 for every $10,000 invested, making it competitive among similar products and enhancing net returns for investors.
- Robust Portfolio Composition: The ETF tracks the Dow Jones U.S. Dividend 100 Index, comprising 100 stocks with a history of at least 10 years of dividend payments, ensuring financial health among constituents and reducing the risk of dividend cuts due to financial troubles, thus enhancing long-term investment safety.
- Diversified Holdings Structure: The top ten holdings account for about 43% of the ETF, with 18% in consumer defensive stocks, 15% in energy, and 18% in healthcare, providing a diversified allocation that helps maintain stability and risk resistance in the event of a market pullback.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRK
Wall Street analysts forecast MRK stock price to fall
16 Analyst Rating
11 Buy
5 Hold
0 Sell
Moderate Buy
Current: 120.760
Low
95.00
Averages
119.53
High
139.00
Current: 120.760
Low
95.00
Averages
119.53
High
139.00
About MRK
Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CMS Proposes Permanent Framework for Medicare Drug Price Negotiations
- Drug Price Negotiation Framework: CMS proposes a permanent framework for negotiating prices on up to 20 drugs in 2029 and beyond, enhancing Medicare's ability to control drug costs effectively.
- Regulatory Implementation Requirement: As mandated by law, the negotiation program must transition from guidance to codified regulations, ensuring long-term effectiveness and providing a stronger legal foundation for drug price negotiations.
- Policy Clarification: The new rule will clarify two elements affecting Part D, including formulary inclusion policies for selected drugs and the definition of 'negotiated price,' thereby increasing transparency and consistency in drug selection.
- Compliance Concerns: The proposal will also narrow the modification of the policy used to identify qualifying single-source drugs to address potential program integrity issues posed by certain new formulations, ensuring fairness and transparency in the drug market.
See More
Merck's PD-1 and HIF-2α Inhibitor Combination Approved
- Clinical Trial Success: The Phase 3 LITESPARK-022 trial demonstrated that the combination of KEYTRUDA and WELIREG reduced the risk of disease recurrence, metastasis, or death by 28%, marking a significant breakthrough in renal cell carcinoma treatment.
- FDA Approval: The U.S. FDA has approved the combination of KEYTRUDA and WELIREG for the adjuvant treatment of intermediate-high risk renal cell carcinoma patients, representing a milestone for WELIREG in earlier-stage disease.
- Patient Benefits: The combination therapy achieved a 24-month disease-free survival rate of 81%, significantly higher than the 74% in the KEYTRUDA plus placebo group, providing a new treatment option that may improve long-term survival for high-risk patients.
- Safety Concerns: While the combination therapy is effective, attention must be paid to potential severe side effects from WELIREG, such as severe anemia and hypoxia, necessitating regular monitoring of relevant indicators during treatment to ensure patient safety.
See More
Merck's Drug Receives FDA Label Expansion Approval
- FDA Approval Expansion: The U.S. FDA approved Merck's oral HIF-2α inhibitor Welireg for label expansion in combination with anti-PD1 inhibitor Keytruda for renal cell carcinoma, marking a significant advancement in kidney cancer treatment.
- Indication Update: Welireg is now indicated as an adjuvant therapy for adults with renal cell carcinoma who have undergone prior nephrectomy, which broadens its clinical application potential.
- Clinical Trial Support: Data from the LITESPARK-022 trial demonstrated that patients receiving Welireg plus Keytruda experienced statistically significant improvements in disease-free survival compared to those on placebo, highlighting the efficacy of this combination therapy.
- Optimistic Market Outlook: Previously approved as a late-line treatment for advanced renal cell carcinoma, this label expansion is expected to enhance Merck's competitive position in oncology and drive sales growth.
See More
Phibro Animal Health Corporation Earnings Analysis
- Core Business Growth: Phibro Animal Health Corporation reported adjusted earnings per share of $0.76 for fiscal Q3 2026, an 18.75% increase from $0.64 in the prior year, exceeding market expectations by 5.92%, indicating strong execution in its core Animal Health segment.
- Strong Revenue Performance: The company achieved a 10.3% year-over-year revenue growth to $383.5 million in Q3, surpassing consensus by 6.26%, with net sales in the Animal Health segment rising 13% to $291.2 million, driven by robust demand for medicated feed additives and vaccines.
- Margin Improvement: Despite a 6% increase in cost of goods sold, gross profit rose 20.2% year-over-year to $125.6 million, with gross margin expanding by 271 basis points to 32.8%, reflecting improvements in product mix and operational execution that helped offset cost pressures.
- Optimistic Future Outlook: Management updated fiscal 2026 guidance, expecting net sales in the range of $1.46 to $1.50 billion, implying 14% growth, and adjusted earnings per share projected between $2.98 and $3.10, representing a 45% improvement over fiscal 2025, showcasing confidence in continued Animal Health execution.
See More
Merck Acquires TARGAN to Expand Poultry Business
- Acquisition Agreement: Merck Animal Health announced the acquisition of biodevice solutions developer TARGAN, with the transaction expected to close in Q3 2026, enhancing its competitive position in the commercial poultry market despite undisclosed financial terms.
- Technology Integration: The acquisition will add TARGAN's automated gender identification device, WingScan, to Merck's portfolio, improving its technological capabilities in the poultry industry to meet market demands for efficient vaccination solutions.
- Vaccine Technology Innovation: TARGAN's ocular spray technology for administering respiratory and other vaccines to newly hatched chicks enhances Merck's diversity and effectiveness in animal health solutions, addressing critical health needs in poultry.
- Shareholder Relationship: Founded in 2015, TARGAN has counted Merck as a major shareholder since 2017, and this acquisition further solidifies their strategic partnership, indicating ongoing investment in the animal health sector.
See More
Merck Animal Health Acquires TARGAN to Enhance Poultry Portfolio
- Acquisition Agreement: Merck Animal Health has announced a definitive agreement to acquire TARGAN, enhancing its biodevice solutions in the poultry sector, with the transaction expected to close in the third quarter of 2026, thereby solidifying Merck's market position in animal health.
- Technology Expansion: The acquisition will expand Merck's poultry portfolio with TARGAN's WingScan technology, an automated chick sex-sorting system capable of processing up to 160,000 chicks per hour, significantly improving efficiency and accuracy in poultry sorting.
- Vaccination Technology Enhancement: The deal also introduces high-speed precision ocular spray technology for administering vaccines to day-old chicks, enhancing Merck's device development capabilities across multiple animal species and increasing its competitive edge in the market.
- Investment Background: Merck has been an investor in TARGAN since 2017 and is one of its largest shareholders, making this acquisition a deepening of its investment and reflecting the company's commitment to the growth potential in the poultry industry.
See More
CMS Proposes Permanent Framework for Medicare Drug Price Negotiations
- Drug Price Negotiation Framework: CMS proposes a permanent framework for negotiating prices on up to 20 drugs in 2029 and beyond, enhancing Medicare's ability to control drug costs effectively.
- Regulatory Implementation Requirement: As mandated by law, the negotiation program must transition from guidance to codified regulations, ensuring long-term effectiveness and providing a stronger legal foundation for drug price negotiations.
- Policy Clarification: The new rule will clarify two elements affecting Part D, including formulary inclusion policies for selected drugs and the definition of 'negotiated price,' thereby increasing transparency and consistency in drug selection.
- Compliance Concerns: The proposal will also narrow the modification of the policy used to identify qualifying single-source drugs to address potential program integrity issues posed by certain new formulations, ensuring fairness and transparency in the drug market.
See More
Merck's PD-1 and HIF-2α Inhibitor Combination Approved
- Clinical Trial Success: The Phase 3 LITESPARK-022 trial demonstrated that the combination of KEYTRUDA and WELIREG reduced the risk of disease recurrence, metastasis, or death by 28%, marking a significant breakthrough in renal cell carcinoma treatment.
- FDA Approval: The U.S. FDA has approved the combination of KEYTRUDA and WELIREG for the adjuvant treatment of intermediate-high risk renal cell carcinoma patients, representing a milestone for WELIREG in earlier-stage disease.
- Patient Benefits: The combination therapy achieved a 24-month disease-free survival rate of 81%, significantly higher than the 74% in the KEYTRUDA plus placebo group, providing a new treatment option that may improve long-term survival for high-risk patients.
- Safety Concerns: While the combination therapy is effective, attention must be paid to potential severe side effects from WELIREG, such as severe anemia and hypoxia, necessitating regular monitoring of relevant indicators during treatment to ensure patient safety.
See More
Merck's Drug Receives FDA Label Expansion Approval
- FDA Approval Expansion: The U.S. FDA approved Merck's oral HIF-2α inhibitor Welireg for label expansion in combination with anti-PD1 inhibitor Keytruda for renal cell carcinoma, marking a significant advancement in kidney cancer treatment.
- Indication Update: Welireg is now indicated as an adjuvant therapy for adults with renal cell carcinoma who have undergone prior nephrectomy, which broadens its clinical application potential.
- Clinical Trial Support: Data from the LITESPARK-022 trial demonstrated that patients receiving Welireg plus Keytruda experienced statistically significant improvements in disease-free survival compared to those on placebo, highlighting the efficacy of this combination therapy.
- Optimistic Market Outlook: Previously approved as a late-line treatment for advanced renal cell carcinoma, this label expansion is expected to enhance Merck's competitive position in oncology and drive sales growth.
See More
Phibro Animal Health Corporation Earnings Analysis
- Core Business Growth: Phibro Animal Health Corporation reported adjusted earnings per share of $0.76 for fiscal Q3 2026, an 18.75% increase from $0.64 in the prior year, exceeding market expectations by 5.92%, indicating strong execution in its core Animal Health segment.
- Strong Revenue Performance: The company achieved a 10.3% year-over-year revenue growth to $383.5 million in Q3, surpassing consensus by 6.26%, with net sales in the Animal Health segment rising 13% to $291.2 million, driven by robust demand for medicated feed additives and vaccines.
- Margin Improvement: Despite a 6% increase in cost of goods sold, gross profit rose 20.2% year-over-year to $125.6 million, with gross margin expanding by 271 basis points to 32.8%, reflecting improvements in product mix and operational execution that helped offset cost pressures.
- Optimistic Future Outlook: Management updated fiscal 2026 guidance, expecting net sales in the range of $1.46 to $1.50 billion, implying 14% growth, and adjusted earnings per share projected between $2.98 and $3.10, representing a 45% improvement over fiscal 2025, showcasing confidence in continued Animal Health execution.
See More
Merck Acquires TARGAN to Expand Poultry Business
- Acquisition Agreement: Merck Animal Health announced the acquisition of biodevice solutions developer TARGAN, with the transaction expected to close in Q3 2026, enhancing its competitive position in the commercial poultry market despite undisclosed financial terms.
- Technology Integration: The acquisition will add TARGAN's automated gender identification device, WingScan, to Merck's portfolio, improving its technological capabilities in the poultry industry to meet market demands for efficient vaccination solutions.
- Vaccine Technology Innovation: TARGAN's ocular spray technology for administering respiratory and other vaccines to newly hatched chicks enhances Merck's diversity and effectiveness in animal health solutions, addressing critical health needs in poultry.
- Shareholder Relationship: Founded in 2015, TARGAN has counted Merck as a major shareholder since 2017, and this acquisition further solidifies their strategic partnership, indicating ongoing investment in the animal health sector.
See More
Merck Animal Health Acquires TARGAN to Enhance Poultry Portfolio
- Acquisition Agreement: Merck Animal Health has announced a definitive agreement to acquire TARGAN, enhancing its biodevice solutions in the poultry sector, with the transaction expected to close in the third quarter of 2026, thereby solidifying Merck's market position in animal health.
- Technology Expansion: The acquisition will expand Merck's poultry portfolio with TARGAN's WingScan technology, an automated chick sex-sorting system capable of processing up to 160,000 chicks per hour, significantly improving efficiency and accuracy in poultry sorting.
- Vaccination Technology Enhancement: The deal also introduces high-speed precision ocular spray technology for administering vaccines to day-old chicks, enhancing Merck's device development capabilities across multiple animal species and increasing its competitive edge in the market.
- Investment Background: Merck has been an investor in TARGAN since 2017 and is one of its largest shareholders, making this acquisition a deepening of its investment and reflecting the company's commitment to the growth potential in the poultry industry.
See More
